Authors

Latest:

Patients Coping With Insomnia May Benefit from Behavioral Interventions

Cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based stress reduction (MBSR) can improve sleep for patients with cancer, but CBT-I continues to be the best nonpharmacologic option

Hayley Virgil

Senior Editor,

Latest:

Olaparib Plus Abiraterone/Prednisone Displays Efficacy in mCRPC

Frontline treatment with olaparib plus abiraterone/prednisone led to a PFS benefit vs olaparib or abiraterone/prednisone alone in BRCA1/2– or ATM–altered mCRPC.

Haythem Y. Ali, MD

Latest:

Dr. Ali on the Need to Understand Real-World Disparities in BRCA Testing in TNBC

Haythem Y. Ali, MD, member, Henry Ford Cancer Institute, Henry Ford Health System, discusses the need to understand real-world disparities with BRCA testing referrals and uptake in patients with triple-negative breast cancer.

He James Zhu, MD, PhD

Latest:

Dr. Zhu on Mitigating Toxicities of Elective Nodal Irradiation in Breast Cancer

He James Zhu, MD, PhD, discusses potential strategies to mitigate the toxicities of elective nodal irradiation in breast cancer.

Hearn Jay Cho, MD, PhD

Latest:

Dr. Cho on Investigational BiTE Therapies in Multiple Myeloma

Hearn Jay Cho, MD, PhD, discusses investigational bispecific T-cell engager therapies in multiple myeloma.

Latest:

Adjuvant Osimertinib in Early-Stage NSCLC: The ADAURA Trial

Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

Heather A. Wakelee, MD, FASCO

Latest:

Monitoring Patients With RET-Positive NSCLC

Panelists discuss how to monitor patients for response to treatment and early signs of resistance in RET fusion–positive non–small cell lung cancer (NSCLC), including the approach to follow-up molecular testing, and describe strategies for treatment sequencing after disease progression on RET inhibitors.

Heather A. Wakelee, MD, Stanford University Medical Center

Latest:

Experts on the Evaluation of CEACAM5-Targeted Therapy in NSCLC

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the evaluation of CEACAM5 biomarker testing in non–small cell lung cancer.

Heather A. Zierhut, PhD, MS, CGC

Latest:

New Law Widens Access to Genetic Counseling but Licensure and Coverage Barriers Persist

Telehealth, a universal term for the use of digital information and communication technologies to remotely access healthcare services, is improving availability of healthcare services, particularly for patients in rural areas.

Heather Dalton, MD

Latest:

Dr. Dalton on Toxicities in the Frontline Treatment of Ovarian Cancer

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses toxicities in the frontline treatment of patients with ovarian cancer.

Heather Greene, NP

Latest:

Toxicities Associated With VEGF TKIs and Checkpoint Inhibitors in mRCC

Heather Greene, a nurse practitioner at West Cancer Center, discusses the toxicities that are associated with VEGF TKIs and checkpoint inhibitors in metastatic renal cell carcinoma (mRCC).

Heather H. Cheng, MD, PhD

Latest:

Dr. Cheng on the Goals of the GENTleMEN Trial in Prostate Cancer

Heather H. Cheng, MD, PhD, discusses the goals of the ongoing GENTleMEN trial in prostate cancer.

Heather L. McArthur, MD, MPH, Cedars-Sinai Medical Center

Heather Leitch, MD, PhD, St. Paul’s Hospital

Heather S. Han, MD

Latest:

Dr. Han on the APHINITY Trial in HER2+ Early-Stage Breast Cancer

Heather S. Han, MD, discusses the benefit of adding pertuzumab to trastuzumab and chemotherapy in the phase 3 APHINITY trial in patients with HER2-positive early-stage breast cancer.

Heather S. Jim, PhD

Latest:

Dr. Jim on Real-World Quality of Life Outcomes With Axi-Cel in R/R LBCL

Heather Jim, PhD, discusses a real-world analysis, examining the quality of life outcomes seen with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.

Heather Wakelee, MD

Latest:

Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

The panel discusses treatment considerations for consolidation durvalumab.